(E)-ethyl 3-(4-((6-hydroxy-2-(2-isopropylphenyl)benzo [b]thiophen-3-yl)oxy)phenyl)acrylate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-ethyl 3-(4-((6-hydroxy-2-(2-isopropylphenyl)benzo [b]thiophen-3-yl)oxy)phenyl)acrylate
• 英文别名: ethyl (E)-3-[4-[[6-hydroxy-2-(2-propan-2-ylphenyl)-1-benzothiophen-3-yl]oxy]phenyl]prop-2-enoate
• 化学式: C₂₈H₂₆O₄S
• 分子量: 458.6
• InChiKey: JWARQLCUZWQRCX-LFIBNONCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  84
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
  申请人：NOVARTIS AG

  公开号：US20170112805A1

  公开（公告）日：2017-04-27

  The present invention relates to compounds of formula I: in which n, m, X, Y 1 , R 1 , R 2 , R 3 , R 4 and R 5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.

  本发明涉及公式I的化合物：其中n，m，X，Y1，R1，R2，R3，R4和R5在发明摘要中定义；能够同时作为雌激素受体的强拮抗剂和降解剂。本发明还提供了制备本发明化合物的方法，包含这些化合物的药物制剂，以及使用这些化合物和组合物在管理与异常雌激素受体活性相关的疾病或紊乱的方法。
• US9321746B2
  申请人：——

  公开号：US9321746B2

  公开（公告）日：2016-04-26
• US9561211B2
  申请人：——

  公开号：US9561211B2

  公开（公告）日：2017-02-07
• US9931317B2
  申请人：——

  公开号：US9931317B2

  公开（公告）日：2018-04-03
• [EN] BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS<br/>[FR] DÉRIVÉS DE BENZOTHIOPHÈNE ET COMPOSITIONS CORRESPONDANTES EN TANT QU'AGENTS DE DÉGRADATION SÉLECTIFS DES RÉCEPTEURS DES ŒSTROGÈNES
  申请人：NOVARTIS AG

  公开号：WO2014130310A1

  公开（公告）日：2014-08-28

  The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.